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In this study, 39 humanhepatocellular carcinoma (HCC) tissues and 7 normal adult liver tissueswere screened for heterozygous polymorphisms in IGF2,
H19, and the differentially methylated region ofH19 (H19DMR) using PCR–RFLP and PCR sequencing. The imprinting of IGF2 andH19was examined
by RT-PCR–RFLP, while the methylation profile of H19DMR was detected by bisulfite sequencing from every informative sample. Of the informative
HCC samples 47.06% (8 of 17) demonstrated a gain of imprinting of IGF2, and 21.74% (5 of 23) of the informative HCC samples demonstrated a loss of
imprinting ofH19. Interestingly, we found threemethylation profiles forH19DMR in the informative HCC samples: hyper-, medium-, and hypomethylated
profiles. Furthermore, the hypomethylated and hypermethylated profiles were immediately associated with aberrant imprinting of IGF2 and H19.
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ental allele due to epigenetic modifications. Insulin-like growth
factor 2 (IGF2) and H19 are two imprinted genes located ad-
jacent to each other at chromosome 11p15.5 in humans. IGF2,
which encodes a protein functioning as a fetal growth factor and
a cell mitogen, is expressed only from the paternal allele in most
tissues [1,2]. H19, which acts as an RNA, is a gene of unknown
function and expressed only from the maternal allele [3,4].
The mechanism of imprinting of IGF2 and H19 is not clearly
revealed. One understanding is that differentially methylated re-
gions (DMRs)may act as epigenetic modifiers of allelic expression
by recruiting proteins specifically binding to methylated or un-
methylated DNA [5–10], which come after an experimental dele-
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doi:10.1016/j.ygeno.2008.01.007isH19DMR,which ismethylated only on the paternal allele in both
mouse and human [5] and is regarded as a key domain for the
control of imprinting of IGF2 and H19 because deletion of this
region results in loss of imprinting of both IGF2 andH19 [6]. This
region contains four specific binding sites for a vertebrate enhancer-
blocking protein CTCF (CCCTC-binding factor) in the mouse,
while it contains seven CTCF binding sites in human [7–9]. One of
the putative explanations for imprinting is the enhancer competition
model, in which IGF2 andH19 promoters compete with each other
on the same chromosome for a set of shared H19 downstream
enhancers, while CTCF binds the unmethylatedmaternal allele and
acts as an insulator between the IGF2 promoter and the enhancers,
thereby suppressing IGF2 transcription maternally. Methylation of
the paternal allele prevents CTCF binding, thereby precluding the
establishment of the insulator and allowing IGF2 transcription
paternally [10].
Abnormal imprinting of IGF2 and/or H19, resulting in a
gain or loss of imprinting, commonly occurs in various types of
cancer and may be involved in malignant transformation [11].
Gain of imprinting (GOI) is the setting up of the “mark” causing
444 J. Wu et al. / Genomics 91 (2008) 443–450expression of either the maternal or the paternal allele, whereas
loss of imprinting (LOI) is the removal of the “mark,” leading to
biallelic expression of genes. The mechanisms for GOI and LOI
are not elucidated, although a large number of studies have been
focused on the modification of DMRs [12–16]. In Wilms'
tumor, it was shown that the aberrant hypermethylation of a
CTCF binding site within H19DMR was necessary but not
sufficient for LOI of IGF2 [12]. And in colorectal cancer, one
study reported that LOI of IGF2 correlated strongly with
maternal hypermethylation of the sixth CTCF binding site in
H19DMR [13]. However, another report suggested that hyp-
omethylation of the paternal DMR within IGF2 intron 2 but not
the H19DMR was a mechanism for IGF2 LOI in human colon
[14]. Additionally, hypomethylation in the paternal H19DMR
was found in partial bladder cancer tissues even without H19
LOI and without the message of the imprinting of IGF2 [15].
More interestingly, in osteosarcoma, it was demonstrated that
IGF2 LOI occurred with biallelic CpG hypermethylation of
H19DMR, while H19 LOI was accompanied by biallelic
hypomethylation of this region, and the methylation status of
IGF2DMR was not uniform [16].
In human liver, the mechanism of imprinting of IGF2 and
H19 would be more complicated because IGF2 is paternally
expressed in fetal liver but changes to biallelic expression in
adult liver. This would result from the promoter usage [17,18].
The human IGF2 gene contains four tissue- and developmental-
specific regulation promoters (P1–P4) [17]. The P1 promoter is
silenced in fetal liver but activated after birth and gradually up-
regulated to produce approximately 50% of the total IGF2Fig. 1. IGF2 and H19 polymorphisms. (A) Schematic of the IGF2/H19 region of c
polymorphism was analyzed in IGF2 exon 9 (ApaI at bp 819); IGF2 bases are numbe
was analyzed in H19 exon 5 (RsaI at bp 12511); H19 bases are numbered as found in
12283, and H19-12679 represent PCR primers for amplification of IGF2 and H19. Pr
the schematic. (B) Actual products of genotype analysis. Representative samples o
polymorphism, according to the above schematic.mRNA in normal adult liver, while in the majority of other
tissues it remains silenced even in the adult. The P3 promoter is
the most active promoter in fetal and newborn human liver and
produces approximately 70% of the total IGF2 transcripts in
this developmental stage of the liver, while it is silenced in the
majority of normal adult livers. Normally, P1 activity is always
biallelic, whereas the other three promoters drive transcription
from only one allele [18].
It has been demonstrated that dysregulated expression of
IGF2 and/or H19 is involved in the hepatocarcinogenesis
[19–21], and both DNMT1 and DNMT3a are strikingly up-
regulated in human hepatocellular carcinoma (HCCs) [22,23].
Although the aberrant imprinting of IGF2 was first observed
many yeas ago [24], there are few reports focused upon the
mechanism of imprinting regulation in HCCs. In this study we
used bisulfite sequencing to investigate the methylation status
of H19DMR in HCC tissues compared with normal adult liver
tissues and study the relationship between the methylation
profile and the allelic expression of IGF2 and H19.
Results
Genotypes of IGF2, H19, and H19DMR in HCC
The schematics of IGF2, H19, and H19DMR polymorph-
isms detected in this study are shown in Fig. 1. By PCR and
RFLP analysis, all 7 normal liver and 17 of 39 HCC samples
were heterozygous for ApaI polymorphism in IGF2 exon 9,
while all 7 normal liver and 23 of 39 HCC samples werehromosome 11p15.5. Locations of PCR primers are indicated by arrows. The
red as found in GenBank Accession No. X07868 (gi: 32998). The polymorphism
GenBank Accession No. AF125183 (gi: 4731323). IGF2-758, IGF2-993, H19-
edicted products for the A and B alleles of each polymorphism are drawn below
f A homozygotes, B homozygotes, and AB heterozygotes are shown for each
445J. Wu et al. / Genomics 91 (2008) 443–450informative for H19 at RsaI and/or AluI in exon 5 (Fig. 1B).
The genotypes of H19DMR at three SNPs were determined by
PCR sequencing for 39 HCC and 7 normal liver tissues. Overall
20 HCCs and 5 normal liver samples were heterozygous in at
least one of the three polymorphisms of H19DMR.
Allelic expression of IGF2 and H19 in HCC
To determine the imprinting status, we analyzed the in-
formative samples for IGF2 and H19 allelic expression by RT-
PCR and RFLP. The results of allelic expression in HCC and
normal liver samples are listed in Table 1 and the typical
samples are shown in Fig. 2. All 7 normal liver samples
informative for IGF2 showed biallelic expression of IGF2,
while 8 of 17 HCC informative samples showed abnormal
monoallelic expression of IGF2, which was so-called gain of
imprinting of IGF2, and the remaining 9 HCC samples showed
seemingly normal biallelic expression of IGF2. Regarding the
H19 gene, all 7 informative normal liver samples showedTable 1
Summary of the imprinting alterations of IGF2/H19 and the average methylation
of H19DMR in normal liver and HCC tissues
Sample IGF2 GOI H19 LOI Average methylation (%)
NL1 No No 51.33
NL2 No No Homo
NL4 No No Homo
NL5 No No 48.00
NL6 No No 41.60
NL7 No No 44.00
NL8 No No 51.50
HCC216 No Yes 77.20
HCC212 No No 72.80
HCC303 Yes No 71.56
HCC213 Homo Yes 70.00
HCC209 Yes Homo 61.82
HCC126 Homo Yes 60.40
HCC214 Yes No 58.18
HCC115 Yes No 55.60
HCC304 Yes Homo 53.67
HCC220 No No 50.80
HCC111 No No 48.44
HCC206 Homo No 46.55
HCC218 Homo No 45.60
HCC128 No No 44.40
HCC217 Homo No 43.60
HCC117 No No 39.60
HCC119 Yes Yes 37.60
HCC116 Homo No 36.50
HCC124 Yes No 35.60
HCC129 No Yes 1.14
HCC208 No No Homo
HCC114 Yes No Homo
HCC123 Homo No Homo
HCC125 Homo No Homo
HCC202 Homo No Homo
HCC301 No Homo Homo
Samples are listedwith their unique numbers. Thirteen sampleswere uninformative
and were not listed to conserve space. Average methylation, percentage of
methylated CpG's in all analyzed CpG's; NL, normal liver sample; HCC, HCC
sample; Homo, homozygous sample of the corresponding SNP site.generally accepted normal monoallelic expression, while 5 of
23 informative HCC samples showed abnormal biallelic ex-
pression of H19, which was so-called loss of imprinting, and
the other 17 HCCs showed seemingly normal H19 imprinting.
Among all of the HCC tissue samples, 12 (12/26; 46.2%)
showed the aberrant imprinting for at least one of the IGF2 and
H19 genes, suggesting that the aberrant imprinting expression
of IGF2 and H19 is a common phenomenon during hepatocel-
lular carcinogenesis.
To address whether the abnormal imprinting of IGF2 was
correlated with aberrant imprinting of H19, we analyzed the
relationship between the imprinting of IGF2 and H19. In the 14
HCC cases informative for both IGF2 and H19, variable patterns
of reciprocal imprinting expression were exhibited: 5 cases with
IGF2 GOI and normal monoallelic expression of H19, 2 cases
with seemingly normal biallelic expression of IGF2 and H19
LOI, 6 cases with seemingly normal biallelic IGF2 expression
and normal monoallelic H19 expression, and 1 case with IGF2
GOI and H19 LOI. No significant correlation was observed
between the allelic expression of IGF2 and H19 (pN0.05).
Methylation profile of H19DMR in HCC
We analyzed the methylation status of the potential
H19DMR containing the sixth CTCF-binding site (CBS6) in
HCC tissues and normal adult liver tissues by bisulfite
sequencing. Three SNPs, but not CpG's, in this region allowed
categorization of clones into groups based on allele of origin.
The target fragment included 27 CpG's, of which the 8th and
the 26th CpG's were excluded when we calculated the
methylation rate because these two CpG's were potential C/T
polymorphisms as well (Fig. 3).
A broken-line graph was drawn to show the methylation
profiles of the normal liver and HCC samples clearly. The
methylation rate of eachCpG sitewas calculated and presented by
a point, and two adjacent points were linked by a line (Fig. 4). The
sum of all 25 CpG sites' methylation rate divided by 25 was the
average methylation of every sample. In all informative normal
liver cases, a medium-methylated profile was observed in the
target region (Fig. 4A). The average methylation ranged from
41.60 to 51.50% (47.28±8.63%, n=5) (Table 1); in other words,
one allelewas nearly all methylated, whereas the other was almost
unmethylated (Fig. 3B). The high variability inmethylation levels
in consecutive CpG's among individuals led to surprisingly
complex methylation patterns in 20 informative HCC cases. The
average methylation in HCCs ranged from 1.14 to 77.20%, even
though the majority of them maintained the allelic differential
methylation(Table 1). The methylation profiles could be grouped
into three discrete methylation categories in HCC samples
compared with normal liver samples: a hypermethylated profile
(average methylationN51.50%: 64.59±16.54%, n=9), a med-
ium-methylated profile (41.60%baverage methylationb51.50%:
46.80±5.17%, n=6), and a hypomethylated profile (average
methylationb41.60%: 30.00±31.77%, n=5). The sequencing
results from three typical HCC samples corresponding to each of
the three different methylation profiles are shown in Figs. 3B
and 4B.
Fig. 2. Genotyping and allelic expression of IGF2 and H19 of representative samples. Representative samples of normal liver (sample NL8), normal imprinting of
IGF2 and H19 (sample HCC128), IGF2 GOI with H19 LOI (sample HCC119), IGF2 GOI with normal H19 imprinting (sample HCC124), and H19 LOI with normal
IGF2 imprinting (sample HCC129) are presented. The “DNA” gels show the results of genotyping for the IGF2 and H19 polymorphisms studied. The “cDNA” gels
show the results of allelic expression analysis by RT-PCR–RFLP.
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imprinting of both IGF2 and H19 in HCC
To address the question whether the three methylation profiles
at the sixth CTCF binding site had an effect on the allele-specific
expression of either IGF2 or H19 in HCC, we analyzed the
relation between IGF2 GOI or H19 LOI and methylation profile.
No obvious correlation was observed for either of them (pN0.05).
However, we found an interested tendency when both IGF2 GOI
and H19 LOI were integrated into one group: all the abnormal
imprinting samples were distributed to either the hypermethylated
group or the hypomethylated group. When the HCCs were
arranged in average methylation order, it could be easily seen that
the samples with abnormal imprinting of IGF2 and/or H19 were
located at the two ends (Table 1). This tendencywas more distinct
for the first 21 CpG's (Fig. 4). It was demonstrated that both
hypermethylation and hypomethylation were associated with
abnormal imprinting of IGF2 and/or H19 (pb0.003).
Discussion
Aberrant imprinting status of IGF2 and/or H19 commonly
occurs in human cancers, while the dysregulation mechanism
remains elusive. In the mouse, the H19DMR is required for
both IGF2 and H19 imprinting [6]. The classical competition
model suggests that the unmethylated maternal H19DMR
allows CTCF binding, establishing an insulator to prevent IGF2
transcription and support H19 transcription. In contrast, the
methylated paternal H19DMR allows for IGF2 transcription
and prevents H19 transcription [8,9]. However, this model
cannot explain many alterations of imprinting occurring in
human cancers [12–16].In this study, we examined the imprinting status of IGF2 and
H19; 47.1% of HCC cases demonstrated GOI of IGF2 and
26.1% of HCC cases showed LOI of H19. IGF2 GOI and H19
LOI occurred at more significant frequencies in HCCs than in
the normal liver samples, which is consistent with previous
reports [24,27], indicating that IGF2 GOI and H19 LOI could
be markers for detection of HCC. As we mentioned previously,
IGF2 has four promoters and normal P1 activity is always
biallelic, whereas other three promoters' activity drives tran-
scription from only one allele. Biallelic expression of IGF2
could not be judged as “normal” because the abnormal biallelic
activation of the P2, P3, or P4 could cause a similar result. And
abnormally silenced P1 promoter as well as a reactivated P3
promoter was found in HCC previously [24]. Moreover, our
results show no striking interrelation of the two genes,
supporting the idea that the H19 transcript itself has no effect
on the imprinting of its neighboring genes, which is derived
from research in mice, despite the fact that noncoding RNA has
been demonstrated to be involved in parent allelic expression at
some loci in mammals [28].
Previously, one group found genome-wide hypomethylation in
HCCs [22]; another Italian group demonstrated that the loss of
maternal-specific methylation at the KvDMR1 locus was common
to a variety of adult neoplasms, including liver, breast, cervical, and
gastric carcinomas [29]; and it has been reported that loss of
parental-specific methylation at the IGF2 exon 8–9 locus was
specifically associated with HCC [30]. Conversely, one report
demonstrated maternal hypermethylation upstream of H19 in
hepatoblastoma [31]. In this studywe first used bisulfite sequencing
to investigate the methylation status of H19DMR in HCC
compared with normal liver control and analyzed the result com-
bined with the allelic expression of IGF2 and H19. Our findings
Fig. 3. Methylation status of individual CpG dinucleotides as determined by bisulfite sequencing. (A) Sketch map of the human H19DMR. An enlarged diagram is
given for each cloned segment. Circles represent the locations of CpG dinucleotides. The locations of single-nucleotide polymorphisms, allowing for the identification
of alleles, are represented by rectangles. Base numbering was performed according to GenBank Accession No. AF125183 (gi: 4731323). In our studied region, there
are 25–27 CpG sites (CpG sites 8 and 26 are polymorphic; C/T). CpG sites 5–9 are located in the core region of the sixth CTCF-binding site. (B) Allele-specific
methylation status of each CpG in every individual. Each line represents one cloned segment, black circles represent methylated CpG's, and white circles represent
nonmethylated CpG's. In every individual, one genotype with methylated CpG sites represents an allele, another genotype represents another allele, and “recombinant”
represents the mosaic genotype.
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CTCF-binding site within H19DMR was immediately associated
with the abnormal imprinting of IGF2 and H19.
Although some reports suggested that the maternal hyper-
methylation at the six binding sites of CTCF within H19DMR
may result in the loss of imprinting of IGF2 in several types of
cancers [12,13,16], no significant correlation was observed
between the IGF2 GOI and the hypermethylation or hypo-methylation at the same region in our results. Both biallelic and
monoallelic expression of IGF2 was demonstrated whatever
the methylation status of H19DMR in these examined HCC
tissues. We could not neglect the influence of the different
promoters' usage and other epigenetic modification before
engaging in further experiments, because the promoters, the
DMR in IGF2, and histone modification play a role in gene
imprinting [14,32].
Fig. 4. Methylation profiles of H19DMR obtained by bisulfite sequencing. (A)
Normal liver samples (n=5). (B) HCC samples (n=20). HCC samples with
IGF2 GOI and/or H19 LOI are highlighted by a red broken line, and others are
shown by a blue broken line.
448 J. Wu et al. / Genomics 91 (2008) 443–450The methylated paternal H19DMR contains a silencer
element responsible for repression of H19 [33], which could
recruit a histone deacetylase through MeCP2 and Sin3a to
repress the chromatin [34]. Nora Engel et al. introduced nine
point mutations into H19DMR to deplete the CpG repeats of
the CTCF-binding sites, and they demonstrated that paternal
inheritance of the mutations resulted in biallelic expression of
H19. This confirmed that the methylation of paternal
H19DMR is necessary for H19 imprinting [35]. Our study
showed that demethylation of paternal H19DMR was linked
with LOI of H19, but there were still several individuals with
H19 LOI displaying allelic differential methylation of the
H19DMR locus. This is consistent with the idea that CTCF
binding at the IGF2/H19 imprinting control region is in-
sufficient to regulate the expression of the two genes in many
human tissues, and even CTCF may be not the only one of
several factors involved in the regulation of genomic
imprinting in human cancer [12,36]. We need further research
on more cases to reveal the mechanism of imprinting.
Moreover, we found that the majority of samples, even
including normal liver, displayed one or more clones with a
“mosaic” pattern of methylation. The proved reason for this was
that maternal/paternal heteroduplex products were created during
the PCR step of the assay, and after being transmitted into
Escherichia coli during the clone procedure, they would be
randomly repaired by the bacterial mismatch repair system [37].
Using sequencing, some mosaic clones proved to be recombinantsas a consequence of the in vivo repair process of heteroduplexes
(Fig. 3B).
The major result in this study was that three degrees of
methylation were first identified in HCCs and the medium-
methylated samples accompanied seemingly normal imprinting,
while the hyper- and hypomethylated samples usually accom-
panied IGF2 GOI and/or H19 LOI. To judge whether the hyper-
and hypomethylated profiles in HCC are abnormal requires more
cases. Nevertheless, it was confirmed that the hyper- and
hypomethylated profiles were strongly associated with the
abnormal imprinting of IGF2 and H19. Many factors might be
involved in themechanism of imprinting regulation in vivo, sowe
could not explain the abnormal imprinting of IGF2 and H19 in
HCC using any putative model alone. The revelation of the
imprinting mechanism requires even more effort.
Materials and methods
Sample collection and nucleic acid isolation
With informed consent of patients, surgically resected tissues from 39 HCCs
from unrelated patients and normal liver tissues from 7 unrelated accidental deaths
were collected in The West China Hospital, Sichuan University, China. All
specimens were confirmed histopathologically. Samples were flash frozen and
stored at –80 °C until used in molecular biology studies. Genomic DNA was
extracted using standard procedures by treatment with proteinase K and phenol–
chloroform extraction, and total RNA was extracted using the single-step
guanidium thiocyanate/acid phenol–chloroform standard method [25].
Genotyping of IGF2, H19, and H19DMR polymorphisms
One potential IGF2 polymorphism, two potential H19 polymorphisms, and
three potential H19DMR polymorphisms are diagrammed in Figs. 1A and 3A.
Genomic DNAs of all 46 samples were analyzed for the above six SNPs by PCR
and RFLP to identify heterozygous samples of IGF2, H19, and H19DMR,
respectively or sequencing. The PCR primer pairs, their optimal annealing
temperatures, and the sizes of the PCR products were listed in Table 2. Each PCR
was performed on aMygene25 plus thermal cycler (LongGene, China) in a 25-μl
volume containing 2.5 μl of PCR buffer (Sangong, China), 250 μM dNTPs, 20
pM appropriate primers, 1 U of Taq DNA polymerase (Sangong), and 300 μg of
genomic DNA. PCR conditions were denaturing at 95 °C for 5 min, followed by
30 cycles of 95 °C for 30 s, optimal annealing temperature for 40 s, and 72 °C for
30 s, and finally 72 °C for 10 min. Then, the PCR products were digested by the
corresponding restriction enzyme (ApaI, RsaI, or AluI) andwere electrophoresed
on 2.5% agarose gels to determine the genotypes of IGF2 andH19. To determine
the genotype of H19DMR, the 405-bp PCR products were purified using an
agarose gel kit (Vitagene, China) and sequenced with the reverse primer by PCR
on an ABI 377 sequence detection system at Shanghai Shenergy Biocolor
Bioscience & Technology Co., Ltd., China.
Analysis of allelic-specific expression of IGF2 and H19
Heterozygous samples for IGF2 and/or H19 polymorphisms were analyzed
for allelic expression by RT-PCR and RFLP. The RNAswere treatedwith RNase-
free DNase (TaKaRa, Japan) before cDNA synthesis. No genomic DNA
contamination was confirmed by performing the identical reaction simulta-
neously in the presence or absence of reverse transcriptase. Reverse transcription
was performed in a volume of 25 μl using 2 μg of RNA, 2.5 μl of 10×RTase
buffer (Promega), 200 U of M-MLV reverse transcriptase (Promega), 50 pM
random hexamer (TaKaRa), and 20U of RNasin (Promega), at 42 °C for 1 h. A 3-
μl aliquot of the product was used as template to amplify the cDNAs with the
same primers, reaction conditions, and temperature profiles of PCR as described
for the above genotyping. The products of the RT-PCR were digested with ApaI,
RsaI, or AluI and then electrophoresed as for genotyping.
Table 2
PCR primers used in this study
Primer Sequence (5′ to 3′) Annealing temperature (°C) PCR product (bp)
Genotyping and allele expression of IGF2 polymorphism (ApaI)
IGF2-758 CTTGGACTTTGAGTCAAATTGG 55 236
IGF2-993 CCTCCTTTGGTCTTACTGGG
Genotyping and allele expression of H19 polymorphism (AluI)
H19-10273 TCAGGAATCGGCTCTGGAAG 58 247
H19-10519 ATGATGTGGTGGCTGGTGGT
Genotyping and allele expression of H19 polymorphism (RsaI)
H19-12283 CCACCACATCATCCCAGAGC 58 397
H19-12679 GAATGCTTGAAGGCTGCTCC
Genotyping of H19DMR polymorphisms (Fig. 3)
H19-7925 GCACGGAATTGGTTGTAGTT 51 405
H19-8329 AGGCAATTGTCAGTTCAGTAA
Cloning analysis of bisulfite-treated DNA (Fig. 3)
H19-7769BT GGAATAATGAGGTGTTTTAGTTTTA 51 602
H19-8370BT CTAACCACTTAAAACTAAAAAAATC
H19-7834BT GTAGGGTTTTTGGTAGGTATAGAGT 51 504
H19-8337BT CACTAAAAAAACAATTATCAATTC
PCR primers are named for the gene they target and the position of the 5′ base as documented in GenBank (Accession No. X07868 for IGF2 primers, AF125183 for all
H19 primers). Primers are labeled BTwhen they were designed to anneal to DNA that had been bisulfite treated. Optimal annealing temperatures were determined by
PCR on a thermal cycler.
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Bisulfite modification was carried out based on the principle that bisulfite
treatment of genomic DNAwould efficiently convert unmethylated cytosines to
uracil, while 5-methylcytosine remained unchanged [26]. To investigate the
allele-specific methylation status of cytosines of H19DMR, the genomic DNAs
of the samples that were heterozygous at H19DMR were required to be bisulfite
treated and then amplified by PCR, finally cloned, and sequenced.
Two micrograms of genomic DNAwas denatured in 50 μl of 0.2 M NaOH at
37 °C for 15 min, and then 30 μl of 10 mM hydroquinone and 520 μl of 3 M
sodium bisulfite, both freshly prepared, were added. The solution was covered
with liquid wax and incubated at 50 °C for 16 h. The bisulfite-treated DNAswere
purified with aWizard Cleanup kit (Promega), then denatured in 100 μl of 0.3 M
NaOH at 37 °C for 5 min, and finally precipitated by ethanol. The purified DNA
was dissolved in 50 μl distilled water, and 3 μl was used for each subsequent
analysis.
Cloning and sequencing of bisulfite-treated DNA
Weadopted the nested-PCRmethod to improve the specificity of amplification.
Two primer pairs were designed for nested-PCR to amplify a region from 2263 to
1760 bp upstream of the H19 transcription start site, which contains the sixth of
seven CTCF-binding sites upstream of H19 (Fig. 3A). The optimal annealing
temperature for each primer pair is given in Table 2. Thermocyclingwas performed
on the Mygene25 Plus thermal cycler (LongGene). An initial preheating step of
5 min at 95 °C was used to melt double-stranded DNA. A touchdown procedure
followed, consisting of 45 s at 95 °C, annealing for 1 min at temperatures
decreasing from 57 to 48 °C for the first 10 cycles (with 1 °C decrease for each
cycle) and at 51 °C for the following 20 cycles, then 45 s at 72 °C, and ending with
an extension step at 72 °C for 10 min. A total of 30 cycles were performed. A 3-μl
sample of the first PCR products from 25 μl total volume was used as the template
for the second PCR. The final 504-bp PCR products were separated on 1.5%
agarose gel, purified using the V-gene gel extraction kit (Vitagene), subsequently
cloned into a pMD18-T vector (TaKaRa) according to the manufacturer's
instructions, and then transformed into JM109 E. coli. The DNA of plasmids from
10 to 20 random positive clones was sequenced for each individual.Statistical analysis
Fisher's exact probabilities test was used to determine whether the
epigenotypes (hyper-, medium-, and hypomethylated profiles) were associated
with allelic expression of IGF2 and H19 (normal versus abnormal imprinting).
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